Home » Stocks » CBIO

Catalyst Biosciences, Inc. (CBIO)

Stock Price: $5.69 USD -0.01 (-0.18%)
Updated November 24, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 125.74M
Revenue (ttm) 18.92M
Net Income (ttm) -50.94M
Shares Out 22.10M
EPS (ttm) -3.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $5.69
Previous Close $5.70
Change ($) -0.01
Change (%) -0.18%
Day's Open 5.71
Day's Range 5.62 - 5.85
Day's Volume 99,242
52-Week Range 3.43 - 8.94

More Stats

Market Cap 125.74M
Enterprise Value 24.30M
Earnings Date (est) Mar 11, 2021
Ex-Dividend Date n/a
Shares Outstanding 22.10M
Float 20.93M
EPS (basic) -3.10
EPS (diluted) -3.06
FCF / Share -1.87
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.11M
Short Ratio 3.21
Short % of Float 5.29%
Beta 2.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.65
PB Ratio 1.37
Revenue 18.92M
Operating Income -52.52M
Net Income -50.94M
Free Cash Flow -41.25M
Net Cash 101.44M
Net Cash / Share 4.59
Gross Margin -231.85%
Operating Margin -277.61%
Profit Margin -269.30%
FCF Margin -218.06%
ROA -31.75%
ROE -58.11%
ROIC -97.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 1
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$19.00*
(233.92% upside)
Low
18.0
Current: $5.69
High
20.0
Target: 19.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue--1.020.401.751.810.5257.8697.6485.71
Revenue Growth--155.14%-77.2%-3.47%246.65%-99.1%-40.74%13.91%-
Gross Profit--1.020.401.751.810.5257.8697.6485.71
Operating Income-57.28-33.83-21.82-20.42-13.80-7.51-10.12-8.14-9.7513.12
Net Income-55.18-30.06-21.56-16.95-14.76-6.61-9.97-7.00-8.5310.90
Shares Outstanding12.0011.213.420.780.300.020.020.320.300.27
Earnings Per Share-4.60-2.68-7.45-21.75-49.99-269.84-409.33-22.05-28.3537.80
Operating Cash Flow-43.61-28.55-19.94-18.47-19.12-6.39-6.27-64.24-83.72138
Capital Expenditures-0.06-0.38-0.020.42-0.270.10-0.041.26-1.43-3.27
Free Cash Flow-43.68-28.93-19.96-18.05-19.39-6.29-6.32-62.98-85.14135
Cash & Equivalents76.8712037.7836.5366.431.8792.33125195214
Total Debt1.80-5.0919.4033.74-1.141.993.233.06
Net Cash / Debt75.0612032.6917.1332.681.8791.19123192211
Assets98.5512539.5138.0969.522.98146190258263
Liabilities30.224.988.7422.0238.103.4611.2613.6683.84171
Book Value68.3412030.7716.0731.43-10913517617491.85
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Catalyst Biosciences, Inc.
Country United States
Employees 34
CEO Nassim Usman

Stock Information

Ticker Symbol CBIO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CBIO

Description

Catalyst Biosciences, a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered next-generation engineered coagulation Factor VIIa that has completed Phase II development for individuals with hemophilia A or B with inhibitors; and Dalcinonacog alfa, a next-generation engineered coagulation Factor IX therapy that has completed Phase IIb clinical trials for the treatment of hemophilia B. The company also develops CB 2679d-GT, an early stage Factor IX gene therapy construct for Hemophilia B; CB 2782-PEG, a long acting anti-C3 protease for the treatment of dry age-related macular degeneration (AMD); and SQ systemic complement inhibitors pipeline. The company has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other serious inflammatory retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.